A Post-Marketing Observational Study of VYXEOS™

Inclusion Criteria: 1. The decision to prescribe VYXEOS must have been made prior to enrollment in this study and based upon approved US indications and dosing: 44mg/m2 daunorubicin and cytarabine 100 mg/2 on Days 1, 3, and 5. 2. Ability to understand and voluntarily give informed consent and understand the requirements of the registry. 3. Age ≥ 18 years. 4. Initiating VYXEOS therapy for the first time according to the current prescribing information. 5. Initiating VYXEOS therapy for the first time according to standard institutional practice. Exclusion Criteria: 1. Prior treatment with VYXEOS. 2. Patients receiving any investigational agent other than VYXEOS (e.g., any drug or biologic agent or medical device that has not received approval in the US) or receiving VYXEOS for any indication not currently approved in the US.